Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Protagonist Therapeutics Inc shares valued at $1,214,678 were sold by PATEL DINESH V PH D on Jul 22 ’25. At $55.05 per share, PATEL DINESH V PH D sold 22,065 shares. The insider’s holdings dropped to 548,538 shares worth approximately $29.48 million following the completion of this transaction.
Also, PATEL DINESH V PH D sold 17,520 shares, netting a total of over 959,921 in proceeds. Following the sale of shares at $54.79 each, the insider now holds 531,018 shares.
Before that, PATEL DINESH V PH D had sold 12,859 shares from its account. In a trade valued at $705,445, the President and CEO traded Protagonist Therapeutics Inc shares for $54.86 each. Upon closing the transaction, the insider’s holdings decreased to 12,859 shares, worth approximately $30.66 million.
As published in their initiating research note from Citigroup on June 17, 2025, Protagonist Therapeutics Inc [PTGX] has been a Buy and the price target has been revised to $72. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in early December. As of December 06, 2024, BMO Capital Markets has initiated its “an Outperform” rating for PTGX. Earlier on November 05, 2024, Wedbush initiated its rating. Their recommendation was “an Outperform” for PTGX stock.
Analyzing PTGX Stock Performance
On last trading session,, Protagonist Therapeutics Inc [NASDAQ: PTGX] plunged -0.83% to $53.74. The stock’s lowest price that day was $53.56, but it reached a high of $54.695 in the same session. During the last five days, there has been a drop of approximately -4.78%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 48.86%. Shares of the company reached a 52-week high of $60.60 on 03/12/25 and a 52-week low of $33.70 on 02/25/25.
Support And Resistance Levels for Protagonist Therapeutics Inc (PTGX)
According to the 24-hour chart, there is a support level at 53.30, which, if violated, would cause prices to drop to 52.86. In the upper region, resistance lies at 54.44. The next price resistance is at 55.13. RSI (Relative Strength Index) is 51.03 on the 14-day chart, showing neutral technical sentiment.
Is Protagonist Therapeutics Inc subject to short interest?
Stocks of Protagonist Therapeutics Inc saw a sharp rise in short interest on 2025-06-30 jumping by 1.52 million shares to 6.73 million. Data from Yahoo Finance shows that the short interest on 2025-05-30 was 5.21 million shares. A jump of 22.62% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.49 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.49.
Which companies own the most shares of Protagonist Therapeutics Inc (PTGX)?
In terms of Protagonist Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 73 in the next 12 months, up nearly 34.71% from the previous closing price of $54.19. Analysts anticipate Protagonist Therapeutics Inc stock to reach 76 by 2025, with the lowest price target being 70. In spite of this, 4 analysts ranked Protagonist Therapeutics Inc stock as Buy at the end of 2025. On September 24, 2024, TD Cowen assigned a price target of “a Buy” to the stock and initiated coverage with a $65.
